Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Global Regulatory Differences for Gene‐ and Cell‐Based Therapies: Consequences and Implications for Patient Access and Therapeutic Innovation
D. Coppens, Marie L. De Bruin, Hubert G. M. Leufkens, et al.
Clinical Pharmacology & Therapeutics (2017) Vol. 103, Iss. 1, pp. 120-127
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe
Renske M.T. ten Ham, Jarno Hoekman, Anke M. Hövels, et al.
Molecular Therapy — Methods & Clinical Development (2018) Vol. 11, pp. 121-130
Open Access | Times Cited: 88
The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost
Vaishali Shukla, Enrique Seoane‐Vazquez, Souhiela Fawaz, et al.
Human Gene Therapy Clinical Development (2019) Vol. 30, Iss. 3, pp. 102-113
Closed Access | Times Cited: 71
Enthesis Tissue Engineering: Biological Requirements Meet at the Interface
Isabel Calejo, Raquel Costa‐Almeida, Rui L. Reis, et al.
Tissue Engineering Part B Reviews (2019) Vol. 25, Iss. 4, pp. 330-356
Open Access | Times Cited: 57
Health Care Evolves From Reactive to Proactive
Scott A. Waldman, André Terzic
Clinical Pharmacology & Therapeutics (2018) Vol. 105, Iss. 1, pp. 10-13
Open Access | Times Cited: 46
Regenerative medicine regulatory policies: A systematic review and international comparison
Tingting Qiu, Eve Hanna, Monique Dabbous, et al.
Health Policy (2020) Vol. 124, Iss. 7, pp. 701-713
Open Access | Times Cited: 34
Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions
Eline van Overbeeke, Sissel Michelsen, Mondher Toumi, et al.
Drug Discovery Today (2020) Vol. 26, Iss. 2, pp. 399-415
Open Access | Times Cited: 34
International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the current state of hematopoietic stem and progenitor cell–based genomic therapies and the challenges faced
Ashish O. Gupta, Melissa Azul, Senthil Velan Bhoopalan, et al.
Cytotherapy (2024) Vol. 26, Iss. 11, pp. 1411-1420
Closed Access | Times Cited: 4
A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making
D. Coppens, Sofieke de Wilde, Henk‐Jan Guchelaar, et al.
Cytotherapy (2018) Vol. 20, Iss. 6, pp. 769-778
Open Access | Times Cited: 32
EU decision-making for marketing authorization of advanced therapy medicinal products: a case study
Sofieke de Wilde, D. Coppens, Jarno Hoekman, et al.
Drug Discovery Today (2018) Vol. 23, Iss. 7, pp. 1328-1333
Open Access | Times Cited: 29
The future of drug development: the paradigm shift towards systems therapeutics
Meindert Danhof, Kevin Klein, Pieter Stolk, et al.
Drug Discovery Today (2018) Vol. 23, Iss. 12, pp. 1990-1995
Open Access | Times Cited: 29
Cellular therapies: Day by day, all the way
Erden Atilla, Pelin Kılıç, Günhan Gürman
Transfusion and Apheresis Science (2018) Vol. 57, Iss. 2, pp. 187-196
Closed Access | Times Cited: 19
Challenges for Cell-Based Medicinal Products From a Pharmaceutical Product Perspective
Dhananjay Jere, Ahmad S. Sediq, Jörg Huwyler, et al.
Journal of Pharmaceutical Sciences (2020) Vol. 110, Iss. 5, pp. 1900-1908
Closed Access | Times Cited: 18
Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit
Inez Johanna, Annet Daudeij, Farah Devina, et al.
Immuno-Oncology Technology (2023) Vol. 20, pp. 100411-100411
Open Access | Times Cited: 6
Regulating Advanced Therapy Medicinal Products through the Hospital Exemption: An Analysis of Regulatory Approaches in Nine EU Countries
D. Coppens, Helga Gardarsdóttir, Marie L. De Bruin, et al.
Regenerative Medicine (2020) Vol. 15, Iss. 8, pp. 2015-2028
Open Access | Times Cited: 13
Patient access to gene therapy medicinal products: a comprehensive review
Marta Carvalho, Bruno Sepodes, Ana Paula Martins
BMJ Innovations (2020) Vol. 7, Iss. 1, pp. 123-134
Open Access | Times Cited: 11
Regulatory oversight of cell therapy in China: Government’s efforts in patient access and therapeutic innovation
Weijia Wu, Yuanyuan Wang, Zhijia Tang, et al.
Pharmacological Research (2020) Vol. 158, pp. 104889-104889
Closed Access | Times Cited: 10
nrichment and preserved functionality of multipotential stromal cells in bone marrow concentrate processed by vertical centrifugation
Jehan J. El‐Jawhari, Dragos C. Ilas, William G. Jones, et al.
European Cells and Materials (2020) Vol. 40, pp. 58-73
Open Access | Times Cited: 9
Illustrative Potency Assay Examples from Approved Therapies
Sílvia Torrents, Marta Grau-Vorster, Joaquim Vives
Advances in experimental medicine and biology (2023), pp. 139-149
Closed Access | Times Cited: 3
Process Improvement for Maximized Therapeutic Innovation Outcome
Scott A. Waldman, André Terzic
Clinical Pharmacology & Therapeutics (2017) Vol. 103, Iss. 1, pp. 8-12
Open Access | Times Cited: 7
Inmunoterapia con células CAR-T en hematooncología pediátrica
Isabel Mirones, Lucas Moreno, Ana Patiño‐García, et al.
Anales de Pediatría (2020) Vol. 93, Iss. 1, pp. 59.e1-59.e10
Open Access | Times Cited: 3
Immunotherapy with CAR-T cells in paediatric haematology-oncology
Isabel Mirones, Lucas Moreno, Ana Patiño‐García, et al.
Anales de Pediatría (English Edition) (2020) Vol. 93, Iss. 1, pp. 59.e1-59.e10
Open Access | Times Cited: 3
Bayesian network analysis of risk classification strategies in the regulation of cellular products
Guoshu Jia, Fu Lixia, Likun Wang, et al.
Artificial Intelligence in Medicine (2024) Vol. 155, pp. 102937-102937
Open Access
Regulatory Environment and Approvals in Cell and Gene Therapy Products Between Japan, the USA, and the EU
Yuya Sato, Shunsuke Ono
Therapeutic Innovation & Regulatory Science (2022) Vol. 57, Iss. 2, pp. 227-237
Closed Access | Times Cited: 2
Regulatory Approaches and Marketing Approvals: A Comparison of Three Systems
Kazuo Yano, Masayuki Yamato
Elsevier eBooks (2018)
Closed Access | Times Cited: 1
Biotechnology applications in clinical trials
Gülay Büyükköroğlu, Behiye Şenel, Emine Şalva, et al.
Elsevier eBooks (2022), pp. 163-195
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top